Compare AGBK & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGBK | KALV |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2014 |
| Metric | AGBK | KALV |
|---|---|---|
| Price | $6.63 | $20.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.20 | ★ $32.60 |
| AVG Volume (30 Days) | 621.7K | ★ 1.2M |
| Earning Date | 03-23-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $187.19 |
| Revenue Next Year | $235.22 | $54.93 |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $6.76 | $9.83 |
| 52 Week High | $12.21 | $21.31 |
| Indicator | AGBK | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 23.66 | 66.43 |
| Support Level | N/A | $14.66 |
| Resistance Level | $7.56 | N/A |
| Average True Range (ATR) | 0.61 | 1.35 |
| MACD | -0.11 | 0.27 |
| Stochastic Oscillator | 5.62 | 82.78 |
AGI Inc is a technology-powered provider of specialized financial services in Brazil. It empowers clients to access their social security benefits, severance fund benefits, and public or private sector payrolls through secured lending solutions and complementary banking, credit and insurance products tailored as per client needs. The company has one operating segment related to the banking business. The Bank provides a standardized set of financial products and services exclusively to individuals, mainly focused on credit, including digital accounts, cards, payroll and personal loans, and insurance offered through partners.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.